MedTrace Logo

Electrical Stimulation Therapy Using the MC5-A Scrambler in Reducing Peripheral Neuropathy Caused by Chemotherapy

NCT00952848 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2017-03-29

Study results available
· View outcomes & findings →

Summary

RATIONALE: Electronic stimulation using a MC5-A Scrambler may help relieve pain in patients who develop peripheral neuropathy while undergoing chemotherapy treatments for cancer.

PURPOSE: This phase II trial is studying how well MC5-A Scrambler therapy works in reducing peripheral neuropathy caused by chemotherapy.

Conditions

Interventions

OTHER

questionnaire administration

Pain Rating Score

OTHER

Sensory Neuropathy Scale instrument

ECOG Common Toxicity Criteria for Sensory Neuropathy scale

OTHER

Quality of Life instrument

Uniscale 0-100 scale global quality of life

DEVICE

MC5-A Scrambler device

Electrical stimulation for 60 minutes

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Virginia Commonwealth University

    lead OTHER

Principal Investigators

  • Thomas J. Smith, MD · Massey Cancer Center

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-12
Primary Completion
2009-10-31
Completion
2010-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00952848 on ClinicalTrials.gov